How Often People with Overweight or Obesity Do Not Follow GLP-1 Receptor Agonist Treatment: A Review of Clinical Trials

Treatment persistence with glucagon-like peptide 1 (GLP-1) agonists may be limited due to adverse drug reactions.

• GLP-1 agonists are commonly utilized for managing obesity in both diabetic and non-diabetic patients.
• Adverse drug reactions (ADRs) are a significant factor affecting patient adherence to treatment.
• Analyzing adherence patterns in randomized controlled trials (RCTs) is important for predicting real-world acceptance of these treatments.

Simplified